Physician profile
Carmine Dalto
NPI 1871553131
$1,252.96
in general payments reported to CMS, 2019-2025
23 companies · $14.37 in 2025
The $14.37 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2021: $34.48 · 2022: $258 · 2023: $496 · 2024: $22.25 · 2025: $14.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $350.17 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $192.47 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Astrazeneca Pharmaceuticals LP | $139.18 | 2019-2023 | Fasenra |
| Mylan Specialty L.P. | $82.73 | 2019-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.08 | 2022-2023 | Ofev |
| Actelion Pharmaceuticals US, INC. | $71.47 | 2019-2023 | Opsumit, Uptravi |
| Pfizer INC. | $42.19 | 2022-2023 | |
| Insmed, INC. | $33.29 | 2019-2023 | Arikayce |
| Novartis Pharmaceuticals Corporation | $28.18 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $27.34 | 2023 | Zerbaxa |
| Shire North American Group INC | $21.75 | 2019 | |
| United Therapeutics Corporation | $20.96 | 2023 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $20.27 | 2023 | Acthar |
| Sunovion Pharmaceuticals INC. | $19.65 | 2021 | |
| Seqirus USA INC | $14.42 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $14.37 | 2025 | Inspire |
| Electromed, INC. | $14.21 | 2023 | Smartvest |
| Amgen INC. | $14.09 | 2023 | Tezspire |
| Hikma Pharmaceuticals USA | $13.63 | 2023 | Ryaltris |
| Genentech USA, INC. | $13.20 | 2022 | |
| Circassia INC. | $13.06 | 2019 | |
| Philips North America LLC | $12.91 | 2022 | |
| Sanofi Pasteur INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmine Dalto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.